Welcome to our dedicated page for Phibro Animal Health Corporation news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal Health Corporation stock.
Phibro Animal Health Corporation (Class A, symbol: PAHC) is a leading global company specializing in animal health and mineral nutrition. With over 40 years of experience, Phibro is dedicated to meeting the rising demand for animal protein by focusing solely on animals used in food production. The company offers a comprehensive range of products for poultry, swine, beef and dairy cattle, and aquaculture.
Phibro's core business involves the development, manufacturing, and marketing of products designed to prevent, control, and treat animal diseases, enhance nutrition, and contribute to balanced mineral nutrition. Their product portfolio includes antibacterials, anticoccidials, nutritional specialty products, and vaccines. The company's operations are divided into three segments: Animal Health, Mineral Nutrition, and Performance Products, with the Animal Health segment being the primary revenue driver.
In the fiscal year ending June 30, 2017, Phibro reported net sales of $764 million. The company employs over 1,400 professionals who are committed to delivering value-based solutions to livestock producers, helping them maintain and enhance the health of their animals. Phibro's products are sold both in the United States and internationally, demonstrating its significant global footprint.
Recent achievements and ongoing projects by Phibro include the development of new vaccines and nutritional specialties aimed at improving animal health and productivity. The company continues to partner with various stakeholders in the livestock industry to innovate and provide sustainable solutions.
Phibro's financial condition remains robust, supported by consistent revenue streams from its diversified product offerings. The company’s focus on research and development underscores its commitment to advancing animal health technologies and addressing the evolving needs of the livestock industry.
For the latest news and updates, Phibro Animal Health Corporation remains a key player in the animal health sector, reflecting its dedication to enhancing the well-being of food animals globally.
Phibro Animal Health Corporation (NASDAQ: PAHC) released its inaugural Environmental, Social and Governance (ESG) Report, establishing baseline key performance metrics as of December 31, 2021. The Report aligns with the Sustainability Accounting Standards Board (SASB) and Global Reporting Initiative (GRI) frameworks, highlighting Phibro’s commitment to sustainable animal health. The company emphasizes its responsibility to provide safe, affordable protein sustainably as global demand rises. Phibro plans to regularly review and update its ESG metrics.
Phibro Animal Health Corporation (Nasdaq: PAHC) reported its Q3 results for the period ending March 31, 2022, showing net sales of $239.6 million, up 13% year-over-year. Net income rose to $17.7 million, a 45% increase. While diluted EPS increased by 47% to $0.44, adjusted net income fell 4% to $13.4 million, with adjusted diluted EPS decreasing by 3%. The company raised its 2022 net sales guidance to $930-$950 million, but maintained adjusted EBITDA at $110-$114 million, amid ongoing macroeconomic challenges.
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) has declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. This dividend is payable on June 22, 2022, to shareholders of record as of the close of business on June 1, 2022. Phibro specializes in developing and supplying a range of animal health and mineral nutrition products, aimed at promoting efficient livestock production.
Phibro Animal Health Corporation (NASDAQ:PAHC) will announce its third quarter financial results on May 4, 2022, after the market closes. A conference call for analysts and investors is scheduled for May 5, 2022, at 9:00 AM Eastern Time. This call will provide insights into the company's performance and future outlook. Interested participants can access the event through Phibro's investor site or by dialing the provided numbers for U.S. and international attendees.
Phibro Animal Health Corporation (NASDAQ:PAHC) is set to participate in the Barclays Global Healthcare Conference on March 15, 2022, at 8:00 AM ET, held in Miami Beach, Florida. CFO Damian Finio will address financial analysts and investors during the event. Attendees can access the live audio presentation through the company's Investor Relations Website. A replay will also be made available afterward. Phibro develops animal health products that aid farmers and veterinarians in producing healthy food sustainably.
Phibro Animal Health Corporation (Nasdaq:PAHC) reported strong financial results for its second quarter ending December 31, 2021, highlighting net sales of $233 million, a 13% increase from the previous year. Net income rose to $17 million, up 36%, with diluted EPS increasing to $0.43, a 34% rise. The company also revised its full-year net sales guidance upward to $890-$920 million. Key revenue drivers included improved demand in Animal Health and Mineral Nutrition segments, despite challenges from rising costs and supply chain issues. Adjusted EBITDA was reported at $29 million.
The Board of Directors of Phibro Animal Health Corporation (NASDAQ: PAHC) declared a quarterly cash dividend of
Phibro Animal Health Corporation (NASDAQ:PAHC) will participate in the BofA Securities 2022 Virtual Animal Health Summit on February 24, 2022, at 12:40 PM ET. CFO Damian Finio and EVP Daniel Bendheim will present to financial analysts and investors. The session will be available live on the company's Investor Relations Website, with a replay archived afterward. Phibro focuses on providing a wide range of animal health and mineral nutrition products, supporting sustainable food production.
Phibro Animal Health Corporation (NASDAQ: PAHC) announced that the FDA will hold a public hearing on March 10, 2022, regarding its product Mecadox® (carbadox). This antibiotic has been used in the U.S. for 50 years to control bacterial diseases in swine. The FDA seeks data on the product's safety, following past concerns about carcinogenic residues. Phibro has been proactively providing research to confirm the product's safety, stating that it will defend its continued market availability. They anticipate the hearing will support the safe use of Mecadox.
Phibro Animal Health Corporation (NASDAQ:PAHC) is set to announce its second quarter financial results on February 9, 2022, after market close. A conference call and webcast will follow on February 10, 2022, at 9:00 AM ET. Interested parties can join via the company's investor relations website or by calling provided numbers. Phibro develops and supplies a range of animal health products, promoting sustainable livestock management and food production. For more details, visit www.pahc.com.
FAQ
What is the current stock price of Phibro Animal Health Corporation (PAHC)?
What is the market cap of Phibro Animal Health Corporation (PAHC)?
What does Phibro Animal Health Corporation do?
Which animals does Phibro's products cater to?
What are the main product categories of Phibro Animal Health Corporation?
How many employees does Phibro Animal Health Corporation have?
How much revenue did Phibro report for the fiscal year ending June 30, 2017?
What are the primary segments of Phibro's operations?
Where does Phibro sell its products?
What recent projects is Phibro involved in?
Who are Phibro's primary customers?
What drives Phibro's revenue?
